SCYNEXIS (SCYX)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	29.27 mm	29.27 mm	29.27 mm	29.27 mm	29.27 mm	29.27 mm
Cash burn (monthly)	2.25 mm	2.44 mm	3.44 mm	4.42 mm	61.00 k	(no burn)
Cash used (since last report)	6.30 mm	6.82 mm	9.63 mm	12.37 mm	170.82 k	n/a
Cash remaining	22.97 mm	22.45 mm	19.64 mm	16.91 mm	29.10 mm	n/a
Runway (months of cash)	10.2	9.2	5.7	3.8	477.1	n/a

Beta Read what these cash burn values mean

Financial data from SCYNEXIS earnings reports.

Institutional ownership, Q3 2024

SCYX institutional ownership history Ownership history

29.4% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	16	5	+220.0%
Opened positions	13	0	NEW
Closed positions	2	1	+100.0%
Increased positions	0	0
Reduced positions	0	1	EXIT

13F shares	Current	Prev Q	Change
Total value	1.32 bn	49.38 mm	+2572.8%
Total shares	10.93 mm	2.94 mm	+272.4%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
FHI Federated Hermes	7.13 mm	$10.62 mm	NEW
Flynn James E	1.50 mm	$0.00	0.0%
Hirschman Orin	1.16 mm	$2.32 mm	0.0%
AMH Equity	600.00 k	$894.00 mm	NEW
Puissance Life Science Opportunities Fund VI	255.72 k	$1.96 mm	0.0%
Wealth Effects	102.00 k	$151.98 mm	NEW
Empowered Funds	100.35 k	$149.52 mm	NEW
Chicago Partners Investment	28.13 k	$41.91 mm	NEW
Bleakley Financial	20.00 k	$29.80 mm	NEW
PDS Planning	15.00 k	$22.35 mm	NEW

Largest transactions	Shares	Bought/sold	Change
FHI Federated Hermes	7.13 mm	+7.13 mm	NEW
AMH Equity	600.00 k	+600.00 k	NEW
Wealth Effects	102.00 k	+102.00 k	NEW
Empowered Funds	100.35 k	+100.35 k	NEW
Chicago Partners Investment	28.13 k	+28.13 k	NEW
DGS Capital Management	0.00	-22.26 k	EXIT
Bleakley Financial	20.00 k	+20.00 k	NEW
PDS Planning	15.00 k	+15.00 k	NEW
Park Avenue Securities	14.00 k	+14.00 k	NEW
Sandy Spring Bank	4.00 k	+4.00 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

SCYX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
12 Sep 24	Gonzalez David Angulo	Common Stock	Buy	Acquire P	No	No	1.37	20,000	27.40 k	507,871
20 Jun 24	Hanham Ann	Common Stock	Grant	Acquire A	No	No	0	23,000	0.00	46,622
20 Jun 24	Hanham Ann	Stock Option Common Stock	Grant	Acquire A	No	No	1.88	23,000	43.24 k	23,000
20 Jun 24	Anido Armando	Common Stock	Grant	Acquire A	No	No	0	23,000	0.00	48,000
20 Jun 24	Anido Armando	Stock Option Common Stock	Grant	Acquire A	No	No	1.88	23,000	43.24 k	23,000
20 Jun 24	Tinmouth Brian Philippe	Common Stock	Grant	Acquire A	No	No	0	23,000	0.00	51,000
20 Jun 24	Tinmouth Brian Philippe	Stock Option Common Stock	Grant	Acquire A	No	No	1.88	23,000	43.24 k	23,000
20 Jun 24	Hastings David C	Common Stock	Grant	Acquire A	No	No	0	23,000	0.00	46,183
20 Jun 24	Hastings David C	Stock Option Common Stock	Grant	Acquire A	No	No	1.88	23,000	43.24 k	23,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

SCYNEXIS Q3 EPS $(0.06) Beats $(0.07) Estimate

6 Nov 24

SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.07) by 14.29 percent. This is a 50 percent decrease over losses of $(0.04) per share from the same

SCYNEXIS To Present Preclinical Data On Second Generation Fungerp SCY-247 At IDWeek 2024

3 Oct 24

SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced upcoming presentations of preclinical

Press releases

From Benzinga Pro

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

6 Nov 24

Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10 million development milestone payment to SCYNEXIS, received in Q3